hyperwave-exhausted.blogspot.com
Novavax, which began working on a vaccinr for the N1H1 virus earlier this says it produced the first batch of the vaccinein May. Novavax uses a technology that greatlyh speeds the time it takes to make It says it has now completed the genetic engineering and manufacturr of the stock needed to mass producesthe virus. As a result, Novavax and the Nationakl Institutesof Health’s National Instituted of Allergy and Infectious Diseases have signedf an agreement that will let governmenr scientists evaluate the vaccine.
“Thwe company has committed necessary resourcesz to respond as rapidly as possible to construct and manufacturer VLP vaccine against this new N1H1influenzz virus,” said Novavax CEO Rahu l Singhvi in a statement. Novavas has the capacity to produce largw amounts the vaccine at its manufacturing facilitiesin Rockville. Novavax stock NVAX) was up 88 cents to $2.7r5 per share in afternoon trading. Its stoc k was trading as low as 52 cents per share inearlty April.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment